1. Home
  2. IRIX vs NRSN Comparison

IRIX vs NRSN Comparison

Compare IRIX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IRIDEX Corporation

IRIX

IRIDEX Corporation

N/A

Current Price

$1.30

Market Cap

25.8M

Sector

Health Care

ML Signal

N/A

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

N/A

Current Price

$0.84

Market Cap

28.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IRIX
NRSN
Founded
1989
2017
Country
United States
Israel
Employees
N/A
15
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
28.4M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
IRIX
NRSN
Price
$1.30
$0.84
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
42.8K
134.0K
Earning Date
04-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
8.47
N/A
EPS
N/A
N/A
Revenue
$41,593,000.00
N/A
Revenue This Year
$9.61
N/A
Revenue Next Year
$8.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$0.68
52 Week High
$1.65
$2.60

Technical Indicators

Market Signals
Indicator
IRIX
NRSN
Relative Strength Index (RSI) 44.87 43.17
Support Level $1.04 $0.68
Resistance Level $1.54 $1.30
Average True Range (ATR) 0.08 0.07
MACD -0.02 -0.00
Stochastic Oscillator 35.85 12.18

Price Performance

Historical Comparison
IRIX
NRSN

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: